BAILEY’S and Christmas go hand in hand, and for many, it’s their favourite part of the festive season. But for those who reach for the

The first study to evaluate the link between Alzheimer’s disease and body weight found a significant association. Researchers at Washington University Medicine in St. Louis,

For Immediate Release Chicago, IL – December 5, 2025 – Today, Zacks Equity Research discusses Eli Lilly LLY, Johnson & Johnson JNJ and Sanofi SNY.

Super Hot ~ Lowest EverGet 120 Capsules JonterKing 50-in-1 GLP-1 Supplement with Akkermansia & Vitamin B, GLP Support, Hunger & Metabolism, Natural Activate Probiotic and

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed both for Type 2 diabetes and weight loss. These drugs also

Over the past three years, Rolls-Royce (LSE:RR) shares have mounted the sort of comeback story normally reserved for Hollywood movies. It has certainly benefitted my

Australia has issued a safety alert on GLP-1 drugs after reviewing reports of depression and suicidal thoughts; while there is no proven causal link, regulators

We came across a bullish thesis on Cal-Maine Foods, Inc. on Fallacy Alarm’s Substack by Rene Bruentrup. In this article, we will summarize the bulls’ thesis on CALM.

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients

Dumb AI, Golden Yuan, & Q-Day Comes Early: Here Are Saxo’s Outrageous Prediction For 2026 The future almost never arrives in straight lines. Whether its’

Could this be the Ozempic for cats? A pharmaceutical company is testing a GLP-1 device that may help cats lose weight. READ: https://www.usatoday.com/story/pets-animals/cat/2025/12/04/overweight-cats-weight-loss-glp-1/87601817007/

Hims & Hers launched in Canada after announcing the company completed its all-cash acquisition of Canadian digital health provider “Livewell”. The deal comes just one

THURSDAY, Dec. 4, 2025 — For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and chronic

The World Health Organization conditionally recommended GLP-1 drugs for obesity. A physician breaks down what you need to know about this historic announcement.

Okava Pharmaceuticals, a biopharmaceutical company, has launched a pilot study of a GLP-1 drug for cats with obesity

Experts say roughly six in 10 cats in the U.S. are carrying too much weight. A new clinical trial, “MEOW-1,” could change that, testing to

Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got

Knownwell delivers weight-inclusive primary care and metabolic health treatment as demand for GLP-1 weight-loss drugs grows and telemedicine rules tighten.

Weight loss drugs for cats? Company launches clinical trial of GLP-1 implants in cats  ABC News Could Weight Loss Drugs Turn Fat Cats Into Svelte Ozempets?  The

ABSTRACT This rapid review aimed to evaluate the effects of GLP-1 RAs on eating behaviors and eating disorder risk. Databases were searched to January 2025

Details of failed studies cast pall on Novo Nordisk’s GLP-1 as Alzheimer’s treatment  Reuters

The joint studies showed some improvement in a few biological measures of the disease, but most of the changes were small and not enough to

On the one hand there is a modest amount of evidence for GLP-1 receptor agonist drugs to produce beneficial effects on an aged metabolism that

As GLP-1 medications like Ozempic have exploded in popularity for humans, researchers from Cornell University are now working on adapting the blockbuster drugs for household

President Trump held his 9th cabinet meeting on Tuesday, highlighting how his administration’s work in negotiating healthcare with Democrats, calling Obamacare “horrible healthcare.” CMS Administrator

The renowned health and wellness platform, Hims & Hers Health, Inc.’s HIMS, business model links virtual consultations directly to prescription access and home delivery. Customers

WEDNESDAY, Dec. 3, 2025 — The oral small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist orforglipron demonstrates superior weight loss as an adjunct to lifestyle modification

Eli Lilly LLY and Novo Nordisk NVO, long-standing rivals and the two dominant forces in the GLP-1 obesity market, are now locked in an intensified battle

Some states are rethinking their coverage of GLP-1 drugs for weight loss as budgets tighten and Medicaid programs brace for the cuts included in President

Two ACR 2025 analyses link SGLT2 inhibitors to fewer RA flares and a lower risk for osteoarthritis than GLP-1 receptor agonists, though randomized trials are

Regarding GLP-1 drugs, 33% of Americans intend to begin taking these medications for weight loss once the Trump administration makes them available at discounted prices

WHO issues conditional recommendations for using these therapies to support people living with obesity in overcoming this serious health challenge, as part of a comprehensive

WHO issues guidance on GLP-1 drugs for obesity, calls them a “scientific breakthrough” and “new chapter”  CBS News WHO issues global guideline on the use of

User engagement in a digital weight-loss program yielded better results in participants taking GLP-1 receptor agonists than nonengagement in the app. Medscape Medical News

Nutrients, Vol. 17, Pages 3789: The Effect of a Low-Energy and Low-Glycemic Diet on Adipose Tissue Metabolism and Energy Expenditure in Women with Excess Body

Post Content

This week, the World Health Organization entered a new arena with its first global guideline on GLP-1 therapies for obesity treatment. Released on December 1,

Talk to your doctor.